Zhongchao (NASDAQ:ZCMD) and 10x Genomics (NASDAQ:TXG) Head to Head Survey

10x Genomics (NASDAQ:TXG) and Zhongchao (NASDAQ:ZCMD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends.

Valuation and Earnings

This table compares 10x Genomics and Zhongchao”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82 million	3.57	-$43.54 million	($0.35)	-51.77
Zhongchao	$15.86 million	0.34	-$640,000.00	N/A	N/A

Zhongchao has lower revenue, but higher earnings than 10x Genomics.

Institutional & Insider Ownership

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 1.7% of Zhongchao shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 28.6% of Zhongchao shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for 10x Genomics and Zhongchao, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	3	9	4	0	2.06
Zhongchao	1	0	0	0	1.00

10x Genomics currently has a consensus price target of $17.68, suggesting a potential downside of 2.44%. Given 10x Genomics’ stronger consensus rating and higher possible upside, analysts clearly believe 10x Genomics is more favorable than Zhongchao.

Volatility and Risk

10x Genomics has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Zhongchao has a beta of -0.08, indicating that its share price is 108% less volatile than the S&P 500.

Profitability

This table compares 10x Genomics and Zhongchao’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
10x Genomics	-6.77%	-6.99%	-5.44%
Zhongchao	N/A	N/A	N/A

Summary

10x Genomics beats Zhongchao on 7 of the 12 factors compared between the two stocks.

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

About Zhongchao

Zhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.